-
More than 20 pharmaceutical companies suspend drug transactions due to inability to produce or delist products
Time of Update: 2022-04-26
On March 16, the Guangzhou Public Resource Trading Center issued a notice on suspending the listing of some drugs on the Internet .
1) and the "Guangzhou Pharmaceutical Group's Procurement on the Internet Procurement Plan" ”, for drugs that cannot be produced normally, products are withdrawn from the market, etc.
-
Institutions get together to investigate the pharmaceutical industry, these four pharmaceutical companies said they have received a number of research institutions
Time of Update: 2022-04-25
During the research process, Teyi Pharmaceutical revealed that the comprehensive gross profit rate of the company's proprietary Chinese medicines is above 70%, and Zhikebao tablets are the company's core product, and the gross profit rate has been maintained at above 80% .
-
The total pass rate of Chinese herbal decoction pieces has increased by over 98%, tending to concentrate the advantages
Time of Update: 2022-04-25
The data shows that there are more than 1,000 Chinese herbal medicine processing enterprises in China, most of which are small in scale, with many production varieties, and the industry market concentration is low .
-
Guocai's new contract renewal game!
Time of Update: 2022-04-25
If the "unit comparable price" of a shortlisted drug meets one of the following conditions, the comprehensive score in the area where the enterprise promises to supply the alliance will be calculated according to the "comprehensive evaluation index system" (see the table in Annex 4 for details), and the one with the highest score will be selected .
-
Domestic 15-valent HPV vaccine approved for clinical trial
Time of Update: 2022-04-25
The HPV market may usher in more strong competitors . Currently the world's highest HPV vaccine variety under developmentCurrently the world's highest HPV vaccine variety under developmentRecently, t
-
The scope of use of the new crown self-test kit announced that the effectiveness of antigen detection can reach up to 99%
Time of Update: 2022-04-25
Not only that, on the second day after the opening of the domestic antigen reagent market, the State Food and Drug Administration issued the "Notice on Doing a Good Job in the Quality and Safety Supervision of New Coronavirus Antigen Detection Reagents", requiring the strengthening of registration-related management, production and operation.
-
The four departments issued an announcement on the "Quality Management Specification for the Production of Chinese Medicinal Materials"
Time of Update: 2022-04-25
The drug supervision and management department shall carry out extended inspections on corresponding Chinese herbal medicine production enterprises, and provide guidance on medicinal requirements, origin processing, and quality inspection .
-
Highlights of adjuvant therapy for NSCLC: T drug became the first and only approved adjuvant immune drug K drug Phase III clinical data released
Time of Update: 2022-04-25
), postoperative treatment with Keytruda reduced the risk of disease recurrence or death by 24% in patients with stage IB to IIIA non-small cell lung cancer (NSCLC) compared with placebo .
-
Multi-pharmaceutical companies such as Xinling Pharmaceutical and Spectrum Bio have completed financing to further enrich their product lines
Time of Update: 2022-04-25
According to news from the investment community on March 18, Xinling Pharmaceutical recently announced the completion of nearly 100 million yuan of Pre-A round of financing .
-
National Medical Insurance Administration: The new coronavirus antigen test is temporarily included in the medical insurance
Time of Update: 2022-04-25
The notice clarifies that it supports the normal operation of medical institutions in severely affected areas, and if necessary, prepays part of the new crown treatment funds according to the procedures .
-
2022 The 9th China International Senior Industry Expo will be held in Beijing on November 13
Time of Update: 2022-04-25
The 2022 ninth China (Beijing) International Aged industry Expo will be held in Beijing on November 13. The 2022 ninth China (Beijing) International Aged industry Expo Chuang International Conventio
-
The price of traditional Chinese medicine is crazy, and it is expected to run at a high level in 2022
Time of Update: 2022-04-25
Recently, I have often heard the news of the price increase of traditional Chinese medicine, such as Jiuzhitang, Tongrentang, China Resources Sanjiu, Zhongxin Pharmaceutical, Taiji Industry and other companies have raised the price of some products .
-
Good news for gastric cancer patients, another drug approved for marketing
Time of Update: 2022-04-25
On March 18, the NMPA website showed that the application status of ramucirumab injection, an innovative anti-VEGFR-2 monoclonal antibody declared by Eli Lilly, has been updated to - approval completed - pending certification, which means The drug is expected to be approved for marketing in China in the near future .
-
Breakthrough therapy drugs ushered in major benefits, and innovative drugs from multi-pharmaceutical companies such as Novartis were included
Time of Update: 2022-04-25
This procedure does not require applicants to apply, and the innovative drug varieties included in the breakthrough therapy drug procedure can automatically carry out follow-up communication and review and approval according to this procedure .
-
China's leading oral medical service Ruier Group successfully landed on the main board of Hong Kong
Time of Update: 2022-04-25
SHANGHAI, March 22, 2022 /PRNewswire/ -- On March 22, Beijing time, Qiming Venture Partners and China's leading oral medical service company, Real Group, was successfully listed on the main board of the Hong Kong Stock Exchange .
-
Pharmaceutical executives continue to flow, and how to retain talent becomes a problem
Time of Update: 2022-04-25
In this regard, the industry believes that for local pharmaceutical companies, although the company may have recruited high-level talents, how to retain them is also becoming an urgent problem to be solved.
-
Positive Phase 3 clinical data of Zai Lab's niraparib in first-line maintenance treatment of ovarian cancer patients in China
Time of Update: 2022-04-25
Data from this phase 3 clinical trial showed that maintenance therapy with niraparib had a statistically and clinically significant benefit in improving PFS in the entire population compared with placebo, regardless of biomarker status; the PRIME study achieved The primary study endpoint, the median PFS of patients in the niraparib group was 24.
-
Boshengji Pharma's CAR-T therapy for neuroblastoma has been granted orphan drug designation by the FDA
Time of Update: 2022-04-25
According to the press release, Boshengji Medicine intends to develop TAA06 injection for the treatment of neuroblastoma .
-
The Ministry of Science and Technology intends to stipulate that my country's human genetic resources shall not be provided to foreign countries
Time of Update: 2022-04-24
The "Implementation Regulations" plan to stipulate that the collection, preservation, utilization and external provision of China's human genetic resources shall respect the privacy rights of human genetic resources providers, obtain prior informed consent, ensure the health of providers and protect their legitimate rights and interests, and shall comply with scientific research activities.
-
250 listed companies released performance reports, and many pharmaceutical companies doubled their net profit
Time of Update: 2022-04-24
The reason for the increase in performance, Zhifei Bio said, is mainly because the company has increased investment in research and development to bring forth new ideas, the sales of independent products and agency products have continued to increase steadily, and the company's main business income, net profit and other important financial indicators are higher than the same period last year.
